Catalyst
Slingshot members are tracking this event:
AstraZeneca's (AZN) ARCTIC trial evaluating durvalumab, tremelimumab, and combination durva + treme against the standard of care for lung cancer patients data expected in November 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN | Community voting in process | |||||
Additional Information
A company spokeswoman said the delay was because the trial had not yet observed enough clinical events in patients.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 24, 2018
Occurred Source:
https://www.astrazeneca.com/media-centre/press-releases/2018/astrazeneca-reports-results-from-the-arctic-trial-in-third-line-non-small-cell-lung-cancer-24042018.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Durvalumab, Tremelimumab, Durva + Treme, Lung Cancer, Arctic
